FMC Corp Earnings Call Balances Progress And Strain

FMC Corp ((FMC)) has held its Q1 earnings call. Read on for the main highlights of the call.

FMC Corp’s latest earnings call struck a cautiously optimistic tone, as management balanced a clear beat versus Q1 guidance and strong innovation progress against persistent pressure on profits, cash flow, and leverage. Executives framed the first half of 2024 as an earnings trough, with gradual improvement expected in the second half and more meaningful upside from 2027, but they also emphasized that execution risk remains high.

Q1 Revenue Beat Masks Modest Underlying Decline

FMC reported first quarter sales of $762 million, about $12 million above the midpoint of guidance and a relative bright spot given sector pressures. Revenue was still down 4% year-over-year, though on a like-for-like basis excluding the divested India business sales edged up 1%, underscoring a fragile recovery rather than a robust rebound.

EBITDA and EPS Outperform Reduced Expectations

Profitability outpaced management’s own conservative outlook, with adjusted EBITDA of $72 million coming in $17 million above the high end of guidance on tighter cost control and mix. Adjusted loss per share of $(0.23) was also better than expected by $0.15 versus the guidance midpoint, helping reassure investors that the company is managing through the downcycle more effectively than feared.

Branded Portfolio and Volumes Show Early Signs of Recovery

Underneath the headline numbers, FMC-branded sales grew 6% on a like-for-like basis and overall volumes increased 2%, suggesting that core demand is stabilizing despite pricing pressure. Foreign exchange was a notable tailwind, adding roughly 5% to reported sales and cushioning the impact of weaker partner revenues and generics competition.

New Active Ingredients Deliver Triple-Digit Growth

Innovation remains a critical pillar of FMC’s equity story, and Q1 showcased strong momentum in new active ingredients. Sales of these products doubled year-over-year, driven by Isoflex, fluindapyr and Dodhylex, and management indicated that this platform should support continued growth with additional product launches slated to begin in 2027.

Isoflex EU Approval Opens a Major Growth Runway

The company achieved a strategic regulatory win with European Union approval of Isoflex, the first new herbicide cleared in the region since 2019. This decision unlocks access to more than 55 million planted hectares across major crops like cereals, corn, oilseed rape and potatoes, with potential upside as preregistrations advance in key markets such as Italy, Germany, France and Spain.

Debt Reduction Plan Builds Visibility, but Not Certainty

FMC reaffirmed its target of roughly $1 billion of debt paydown in 2026, a key focus for equity and credit investors as leverage remains elevated. The planned sale of the India commercial business is in late stages with a definitive agreement expected soon, and management highlighted about $700 million of proceeds already in advanced negotiations across India, licensing, molecules and real estate.

Revolver Amendment Bolsters Liquidity Cushion

To reinforce its funding backstop, the company amended its revolving credit facility, maintaining $2 billion of capacity out to June 2028 while adding a substantial collateral package. The new structure includes around $6 billion of direct liens, potentially rising to roughly $9 billion with guarantees, and sets a secured leverage covenant of 3.5x, well above the approximately 1.3x level FMC would have posted at quarter-end.

Q2 Outlook Calls for Steep Revenue and EBITDA Drop

Near-term fundamentals remain challenging, with management guiding second quarter revenue to $850–$900 million, implying a roughly 17% decline at the midpoint versus last year. Adjusted EBITDA is projected in the $130–$150 million range, which would represent about a 32% year-over-year contraction as lower sales to diamide partners and the removal of India weigh on margins.

Full-Year Guidance Signals Material Earnings Compression

Despite the Q1 beat, FMC kept its full-year outlook intact, and the numbers point to a sizable earnings reset for 2026 versus prior performance. The company anticipates sales around $3.7 billion, down about 5%, with EBITDA near $700 million, down roughly 17%, and adjusted EPS in the $1.63–$1.89 band, implying a decline of about 41% at the midpoint amid margin pressure and higher financing costs.

Interest Expense and Leverage Remain Key Overhangs

Financing costs are rising, with Q1 interest expense at $64.8 million, up $14.7 million year-over-year, and full-year interest now expected between $255 million and $275 million, roughly $25 million higher at the midpoint. Gross debt stands near $4.5 billion with net debt around $4.1 billion, translating to trailing gross and net leverage of about 5.7x and 5.2x EBITDA, respectively, as seasonal working capital and weaker earnings inflate ratios.

Free Cash Flow Swings Deeply Negative in Q1

Cash generation was particularly weak, with first quarter free cash flow at negative $628 million, deteriorating by $32 million versus the prior year period. Management’s full-year guidance range is wide, from negative $65 million to positive $65 million with a breakeven midpoint, and that outlook already assumes roughly $150 million in cash restructuring costs that must be funded in a tight liquidity environment.

Generics and Grower Stress Pressure Pricing Power

Competitive dynamics remain tough, as average prices fell 6% in Q1, with nearly half of that decline tied to lower diamide partner sales. Management cited intense competition in Latin America and Asia, where financially strained growers are increasingly opting for lower-cost generic products or even skipping applications, underscoring ongoing headwinds to FMC’s pricing power and volumes.

Rynaxypyr Transition Creates Near-Term Revenue Headwind

The company detailed a structural shift in its flagship Rynaxypyr franchise as it transitions through the post-patent phase and away from partner-heavy sales. While total Rynaxypyr revenue is expected to ease only modestly from about $800 million to roughly $700 million by 2026, partner-derived sales are forecast to fall below $100 million, driving meaningful near-term revenue pressure during the transition.

Macro, Input Costs and Tariffs Add Another Layer of Risk

FMC also warned about rising input costs and macro uncertainty, pointing to higher energy, transportation and petrochemical prices linked to geopolitical tensions. The company currently assumes that Iran-related cost pressures and tariff recoveries roughly offset each other, but it stressed that volatility is high and that margin and product cost outcomes could swing either way as conditions evolve.

Guidance Points to H1 Trough and Gradual H2 Recovery

Management reaffirmed its detailed outlook, including Q2 revenue of $850–$900 million, EBITDA of $130–$150 million and adjusted EPS of $0.16–$0.26, which would mark a sharp year-on-year EPS decline of about 70% at the midpoint. Looking to 2026, they reiterated guidance for $3.6–$3.8 billion in sales, EBITDA of $670–$730 million, EPS between $1.63 and $1.89, and free cash flow hovering around breakeven, with the debt paydown plan and strengthening new active ingredient portfolio expected to support better performance by 2027.

FMC’s earnings call delivered a mixed message for investors, showcasing solid execution against lowered expectations and real progress on innovation and balance sheet strategy while underscoring a difficult operating backdrop. For now, the stock’s appeal hinges on management’s ability to navigate the earnings trough, execute asset sales and debt reduction, and convert its strong R&D pipeline into sustained, higher-margin growth later in the decade.